(secondQuint)Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model.

 This study consisted of 5 Visits.

 Eligible patients underwent allergy testing using the Conjunctival Allergen Challenge (CAC) model, which reproduces the signs and symptoms of Seasonal Allergic Conjunctivitis by replicating the natural disease process.

 Patients demonstrating a positive reaction to the CAC at Visit 1 (screening) and Visit 2 (confirmatory) were randomized to treatment at Visit 3 (Day 0).

 The test article was instilled at Visit 3, with treatment efficacy CAC performed at 24 hours duration of action.

 The test article was instilled again at Visit 4 (Day 14), with treatment efficacy CAC performed at 16 hours duration of action.

 The test article was instilled a final time at Visit 5 (Day 21), with treatment efficacy performed at onset of action.

.

 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model@highlight

The purpose of this study was to assess the safety and efficacy of AL-4943A ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis using the Conjunctival Allergen Challenge (CAC) model.

